Insulin Glargine vs Standard Care: Number of Patients With First Occurrence of Any Type of Cancer
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0892 | 0.0824 | 0.0966 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0894 | 0.0826 | 0.0967 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.000191 | -0.0102 | 0.0098 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.998 | 0.892 | 1.12 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.998 | 0.882 | 1.13 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Insulin Glargine than on Standard Care | 5,240 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: standard care.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Insulin Glargine | Treatment with Insulin Glargine with or without omega-3 polyunsaturated fatty acids | 559 | 6,264 | OG000 | ClinicalTrials.gov |
| Group 2 | Standard Care | Standard care with or without omega-3 polyunsaturated fatty acids | 561 | 6,273 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | OTHER_PRE_SPECIFIED | ClinicalTrials.gov |
| Title | Number of Patients With First Occurrence of Any Type of Cancer | ClinicalTrials.gov |
| Description | Data on cancers that occurred in association with hospitalizations were collected systematically in both groups from the start of the study. All reported cancers occurring during the trial (new or recurrent) were adjudicated by the Event Adjudication Committee. | ClinicalTrials.gov |
| Time frame | from randomization until study cut-off date (median duration of follow-up: 6.2 years) | ClinicalTrials.gov |
| Population | The analysis was based on the intent-to-treat (ITT) population. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention) | ClinicalTrials.gov |
| NCT number | NCT00069784 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Diabetes Mellitus, Non-Insulin-Dependent | ClinicalTrials.gov |
| Interventions | insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection | ClinicalTrials.gov |
| Lead sponsor | Sanofi | ClinicalTrials.gov |
| Results first posted | 2013-01-25 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT00069784?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.